Patents by Inventor Sreedhara Alavattam
Sreedhara Alavattam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240010732Abstract: The invention provides stable aqueous pharmaceutical formulations comprising an anti-PDL1 antibody. The invention also provides methods for making such formulations and methods of using such formulations.Type: ApplicationFiled: August 2, 2023Publication date: January 11, 2024Applicant: Genentech, Inc.Inventors: Ying YANG, Sreedhara ALAVATTAM
-
Publication number: 20230181533Abstract: The invention provides formulations comprising a protein in combination with a compound that prevents oxidation of the protein. The invention also provides methods for making such formulations and methods of using such formulations. The invention further provides methods of screening for compounds that prevent oxidation of a protein in a protein composition and methods of preventing oxidation of a protein in a formulation.Type: ApplicationFiled: February 3, 2023Publication date: June 15, 2023Inventors: Sreedhara ALAVATTAM, Mary MALLANEY, Parbir GREWAL
-
Patent number: 11654105Abstract: Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.Type: GrantFiled: August 22, 2022Date of Patent: May 23, 2023Assignees: Genentech, Inc., Hoffmann-La RocheInventors: Jennifer Eng-Wong, Whitney Kirschbrown, Tarik Ali Khan, Jasper Lin, Sreedhara Alavattam, Amit Garg, Sarah Heeson, Tanja Badovinac-Crnjevic, Christine Wurth
-
Publication number: 20230092354Abstract: Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.Type: ApplicationFiled: August 22, 2022Publication date: March 23, 2023Applicants: Genentech, Inc., Hoffmann-La Roche Inc.Inventors: Jennifer Eng-Wong, Whitney Kirschbrown, Tarik Ali Khan, Jasper Lin, Sreedhara Alavattam, Amit Garg, Sarah Heeson, Tanja Badovinac-Crnjevic, Christine Wurth
-
Patent number: 11596620Abstract: The invention provides formulations comprising a protein in combination with a compound that prevents oxidation of the protein. The invention also provides methods for making such formulations and methods of using such formulations. The invention further provides methods of screening for compounds that prevent oxidation of a protein in a protein composition and methods of preventing oxidation of a protein in a formulation.Type: GrantFiled: November 22, 2017Date of Patent: March 7, 2023Assignee: F. HOFFMANN-LA ROCHE AGInventors: Sreedhara Alavattam, Mary Mallaney, Parbir Grewal
-
Publication number: 20230048743Abstract: The present application relates to recombinant antibodies that are engineered to alter interactions between the antibodies and one or more endogenous lipases of a host cell used to produce the antibodies. In some cases, the antibodies are mutated in the heavy chain constant region, such as at CH1, CH2, and/or CH3. In other cases, the antibodies are mutated to alter their glycosylation profile.Type: ApplicationFiled: July 8, 2022Publication date: February 16, 2023Applicant: Genentech Inc.Inventors: Elizabeth Sara Hecht, Shrenik Chetan Mehta, Wendy Noel Sandoval, Sreedhara Alavattam, Nathaniel Robert Tzizik-Swanson
-
Publication number: 20210221892Abstract: The invention provides stable aqueous pharmaceutical formulations comprising an anti-PDL1 antibody. The invention also provides methods for making such formulations and methods of using such formulations.Type: ApplicationFiled: November 23, 2020Publication date: July 22, 2021Applicant: Genentech, Inc.Inventors: Ying YANG, Sreedhara ALAVATTAM
-
Publication number: 20210155715Abstract: The present disclosure provides methods and formulations comprising a polypeptide comprising solvent accessible amino acid residues susceptible to oxidation wherein N-acetyl-DL-tryptophan (NAT) and/or L-methionine is used to prevent oxidation of the polypeptide.Type: ApplicationFiled: February 5, 2021Publication date: May 27, 2021Inventors: Cleo SALISBURY, Vikas SHARMA, Sreedhara ALAVATTAM
-
Publication number: 20210085597Abstract: Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.Type: ApplicationFiled: November 19, 2020Publication date: March 25, 2021Applicants: Genentech, Inc., Hoffmann-La Roche Inc.Inventors: Jennifer Eng-Wong, Whitney Kirschbrown, Tarik Ali Khan, Jasper Lin, Sreedhara Alavattam, Amit Garg, Sarah Heeson, Tanja Badovinac-Crnjevic, Christine Wurth
-
Patent number: 10875922Abstract: The invention provides stable aqueous pharmaceutical formulations comprising an anti-PDL1 antibody. The invention also provides methods for making such formulations and methods of using such formulations.Type: GrantFiled: March 25, 2016Date of Patent: December 29, 2020Assignee: Genentech, Inc.Inventors: Ying Yang, Sreedhara Alavattam
-
Patent number: 10849849Abstract: Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.Type: GrantFiled: January 16, 2018Date of Patent: December 1, 2020Assignees: GENENTECH INC., HOFFMANN-LA ROCHE INCInventors: Jennifer Eng-Wong, Whitney Kirschbrown, Tarik Khan, Jasper Lin, Sreedhara Alavattam, Amit Garg, Sarah Heeson, Tanja Badovinac-Crnjevic, Christine Wurth
-
Patent number: 10653779Abstract: The invention provides formulations comprising a protein in combination with a compound that prevents oxidation of the protein. The invention also provides methods for making such formulations and methods of using such formulations. The invention further provides methods of screening for compounds that prevent oxidation of a protein in a protein composition and methods of preventing oxidation of a protein in a formulation.Type: GrantFiled: March 13, 2014Date of Patent: May 19, 2020Assignee: GENENTECH, INC.Inventors: Sreedhara Alavattam, Mary Mallaney, Parbir Grewal
-
Publication number: 20180318256Abstract: The invention provides formulations comprising a protein in combination with a compound that prevents oxidation of the protein. The invention also provides methods for making such formulations and methods of using such formulations. The invention further provides methods of screening for compounds that prevent oxidation of a protein in a protein composition and methods of preventing oxidation of a protein in a formulation.Type: ApplicationFiled: November 22, 2017Publication date: November 8, 2018Inventors: Sreedhara ALAVATTAM, Mary MALLANEY, Parbir GREWAL
-
Publication number: 20180296470Abstract: Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.Type: ApplicationFiled: January 16, 2018Publication date: October 18, 2018Applicants: Genentech, Inc., F. Hoffmann-La Roche AGInventors: Jennifer Eng-Wong, Whitney Kirschbrown, Tarik Khan, Jasper Lin, Sreedhara Alavattam, Amit Garg, Sarah Heeson, Tanja Badovinac-Crnjevic, Christine Wurth
-
Publication number: 20170196837Abstract: The invention provides formulations comprising a protein in combination with a compound that prevents oxidation of the protein. The invention also provides methods for making such formulations and methods of using such formulations. The invention further provides methods of screening for compounds that prevent oxidation of a protein in a protein composition and methods of preventing oxidation of a protein in a formulation.Type: ApplicationFiled: December 20, 2016Publication date: July 13, 2017Inventors: Sreedhara ALAVATTAM, Mary MALLANEY, Parbir GREWAL
-
Publication number: 20160319022Abstract: The invention provides stable aqueous pharmaceutical formulations comprising an anti-PDL1 antibody. The invention also provides methods for making such formulations and methods of using such formulations.Type: ApplicationFiled: March 25, 2016Publication date: November 3, 2016Applicant: Genentech, Inc.Inventors: Ying YANG, Sreedhara ALAVATTAM
-
Publication number: 20160175438Abstract: The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity; and treating HER2-positive cancer by co-administering a mixture of Pertuzumab and Trastuzumab from the same intravenous bag.Type: ApplicationFiled: March 2, 2016Publication date: June 23, 2016Applicant: Genentech, Inc.Inventors: Sreedhara Alavattam, Lukas C. Amler, Mark C. Benyunes, Emma L. Clark, Christina H. de Toledo Pelizon, Zephania W. Kwong Glover, Lada Mitchell, Jayantha Ratnayake, Graham A. Ross, Ru-Amir Walker
-
Publication number: 20160108125Abstract: The invention provides formulations comprising a protein in combination with a compound that prevents oxidation of the protein. The invention also provides methods for making such formulations and methods of using such formulations. The invention further provides methods of screening for compounds that prevent oxidation of a protein in a protein composition and methods of preventing oxidation of a protein in a formulation.Type: ApplicationFiled: May 28, 2015Publication date: April 21, 2016Inventors: Sreedhara ALAVATTAM, Mary MALLANEY, Parbir GREWAL
-
Publication number: 20140322203Abstract: The invention provides formulations comprising a protein in combination with a compound that prevents oxidation of the protein. The invention also provides methods for making such formulations and methods of using such formulations. The invention further provides methods of screening for compounds that prevent oxidation of a protein in a protein composition and methods of preventing oxidation of a protein in a formulation.Type: ApplicationFiled: March 13, 2014Publication date: October 30, 2014Applicant: GENENTECH, INC.Inventors: Sreedhara ALAVATTAM, Mary MALLANEY, Parbir GREWAL
-
Publication number: 20140314778Abstract: The invention provides formulations comprising a protein in combination with a compound that prevents oxidation of the protein. The invention also provides methods for making such formulations and methods of using such formulations. The invention further provides methods of screening for compounds that prevent oxidation of a protein in a protein composition and methods of preventing oxidation of a protein in a formulation.Type: ApplicationFiled: March 13, 2014Publication date: October 23, 2014Applicant: Genentech, Inc.Inventors: Sreedhara ALAVATTAM, Mary MALLANEY, Parbir GREWAL
